ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 233 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,203,768 | -23.2% | 47,200 | -21.3% | 0.03% | -10.5% |
| Q4 2023 | $2,869,200 | +78.8% | 60,000 | +33.3% | 0.04% | +58.3% |
| Q3 2023 | $1,604,250 | -80.7% | 45,000 | -75.0% | 0.02% | -83.8% |
| Q2 2023 | $8,303,400 | +165.4% | 180,000 | +130.7% | 0.15% | +146.7% |
| Q1 2023 | $3,128,762 | +48.4% | 78,024 | +71.5% | 0.06% | +87.5% |
| Q4 2022 | $2,108,015 | -80.2% | 45,500 | -82.3% | 0.03% | -78.2% |
| Q3 2022 | $10,643,000 | -45.2% | 257,100 | -21.0% | 0.15% | -45.1% |
| Q2 2022 | $19,422,000 | +192.7% | 325,534 | +256.2% | 0.27% | +235.0% |
| Q1 2022 | $6,636,000 | -27.3% | 91,400 | +14.0% | 0.08% | -59.2% |
| Q1 2021 | $9,131,000 | +140.7% | 80,201 | +192.7% | 0.20% | +127.9% |
| Q4 2020 | $3,794,000 | -14.5% | 27,400 | -49.3% | 0.09% | -17.3% |
| Q3 2020 | $4,436,000 | -48.3% | 54,000 | -50.8% | 0.10% | -63.6% |
| Q2 2020 | $8,581,000 | +394.9% | 109,700 | +338.8% | 0.29% | +197.9% |
| Q1 2019 | $1,734,000 | – | 25,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |